does microdosing glp-1 work glp 1 Microdosing agonists—using doses below FDA-approved levels for T2D or obesity—is rapidly gaining traction as an off-label strategy to improve tolerability, tailor titration, and manage costs Microdosing GLP-1s: Safety, Dosage, Side

SwissADME-based prediction of drug-likeness and ADMET parameters The selected compounds were comprehensively evaluated for their physicochemical properties, pharmacokinetic profiles, drug-likeness parameters, and medicinal chemistry characteristics through the SwissADME computational platform developed and maintained by the Molecular Modeling Group at the Swiss Institute of Bioinformatics ( o/w ) by combining physics-driven approaches such as iLOGP, which reduces the overfitting tendency, with data-centered models trained on extensive experimental measurements

These examples underscore the potential for GLP-1 RAs to address a wider range of health challenges in the future

Brooks et al., 2017)

Achieving broader access will require innovative pricing models and expanded insurance coverage, particularly for marginalized communities